AhmadTarhiniMDPhD

Clinical Trials

• Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 2006 Oct 01

  Completed

  Phase 1

• VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2007 Jun 01

  Completed

  Phase 2

• Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2008 Oct 01

  Completed

  Phase 1

• Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma Start of enrollment: 2006 Nov 01

  Completed

  Phase 2

• Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia Start of enrollment: 2008 Sep 01

  Terminated

  Phase 1

• Pilot Study of IFN α2b for Melanoma Patients Start of enrollment: 2009 Sep 01

  Terminated

  Early Phase 1

• Melanoma Molecular Profiling Analysis Start of enrollment: 2008 May 01

  Completed

• Computed Tomography (CT) Perfusion Imaging of Lung Cancer Start of enrollment: 2009 Jun 01

  Terminated

  Not Applicable

• Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2009 Jul 01

  Terminated

  Phase 1

• Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer Start of enrollment: 2010 Sep 01

  Terminated

  Phase 2

• Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer Start of enrollment: 2009 Sep 01

  Terminated

  Phase 1

• Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma Start of enrollment: 2009 Dec 01

  Completed

  Early Phase 1

• AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer Start of enrollment: 2011 Aug 01

  Completed

  Phase 1, Phase 2

• Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2011 Jan 18

  Completed

  Phase 2

• Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25

  Active, not recruiting

  Phase 3

• A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03

  Completed

• Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors Start of enrollment: 2012 Jul 24

  Completed

  Phase 1

• Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2013 Jan 18

  Active, not recruiting

  Phase 2

• Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12

  Completed

  Phase 3

• Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Start of enrollment: 2013 Jul 01

  Terminated

  Phase 1, Phase 2

• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 16

  Active, not recruiting

  Phase 3

• Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24

  Active, not recruiting

  Phase 2

• Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Start of enrollment: 2015 Nov 10

  Active, not recruiting

  Phase 3

• Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone Start of enrollment: 2016 Oct 01

  Withdrawn

  Phase 1, Phase 2

• A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study Start of enrollment: 2016 Sep 01

  Terminated

  Phase 2

• Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors Start of enrollment: 2018 May 30

  Active, not recruiting

  Phase 1

• Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma Start of enrollment: 2021 May 24

  Recruiting

  Early Phase 1

• Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma Start of enrollment: 2021 Oct 22

  Recruiting

  Phase 1

• Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma Start of enrollment: 2021 Dec 15

  Recruiting

  Phase 2

  Roles: Principal Investigator, Contact

• Join now to see all